SC
BHVN

Schubert & Co’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Schubert & Co’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10
Closed -$2K – 1668
2022
Q3 		$2K Hold
10
– – ﹤0.01% 969
2022
Q2 		$1K Buy
10
+2
+25% +$255 ﹤0.01% 1424
2022
Q1 		$1K Buy
8
+3
+60% +$374 ﹤0.01% 1047
2021
Q4 		$1K Buy
+5
New +$636 ﹤0.01% 983

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Schubert & Co's BHVN Position: Q4 2022 in Review

Schubert & Co sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 10 shares — an estimated $2K sold.

Schubert & Co first reported a position in BHVN in Q4 2021 and held it in 4 quarters. The position peaked at $2K in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Schubert & Co reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Schubert & Co sold 10 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $2K.
  • Schubert & Co first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 4 quarters.
  • Schubert & Co's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Schubert & Co's 13F filing for Q4 2022, filed 1 Feb 2023.